In a first, CMS will test paying less for drugs cleared via accelerated approval

Zachary Brennan

Senior Editor

The Centers for Medicare and Medicaid Services said Tuesday afternoon that it will start testing a program to pay drugmakers less for drugs approved via …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

In a first, CMS will test paying less for drugs cleared via accelerated approval

Zachary Brennan

Senior Editor

Sign up to read this article for free.

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

In a first, CMS will test pay­ing less for drugs cleared via ac­cel­er­at­ed ap­proval

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

In a first, CMS will test paying less for drugs cleared via accelerated approval

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B